Aptuit And Chiesi Collaborate To Treat Idiopathic Pulmonary Fibrosis
Aptuit, LLC, a premier global drug discovery and development CRO, and Chiesi Farmaceutici (Chiesi), an international research-focused Healthcare Group, announced today that they have entered an agreement under which Aptuit will conduct an integrated Discovery Project aimed at providing innovative drugs to treat Idiopathic Pulmonary Fibrosis.
Both parties will contribute scientifically, with Aptuit providing integrated early Discovery capabilities, including Medicinal Chemistry and Pharmacology, as well as Drug Metabolism and Pharmacokinetics, in order to identify promising compounds for further pre-clinical development.
Dr. Jonathan Goldman, Chief Executive Officer, Aptuit, stated, “This project builds upon the existing relationship between Chiesi and Aptuit in the field of Respiratory Drug Discovery. We are delighted to be working with Chiesi to identify early stage compounds that we hope will ultimately progress into innovative treatments for patients with this debilitating disease”.
Dr. Mark Parry Billings, Corporate Drug Development Head, Chiesi Farmaceutici, commented, “We are very pleased to announce the partnership with Aptuit. We share a common culture of scientific excellence and commitment to quality research and development. This alliance will allow our Project to progress effectively to the identification of lead compounds with a novel mechanism of action, leveraging our joint expertise in Respiratory drug discovery”.
Please note: The content above may have been edited to ensure it is in keeping with Technology Networks’ style and length guidelines.
Worms Exhibit Fear and Respond to Anti-anxiety MedsNews
A team of investigators has uncovered new clues about the mechanisms of fear and anxiety through an unlikely creature: the tiny nematode worm.READ MORE
SMi’s 5th Annual Molecular Diagnostics Conference 2018 Agenda ReleasedNews
SMi proudly presents its 5th annual conference on Molecular Diagnostics, taking place at the Holiday Inn Kensington Forum, London, UK on 9th and 10th July 2018, with a half-day post-conference workshops on 11th July 2018.READ MORE
Antimicrobial Found in Toiletries Could be Used Against MalariaNews
Triclosan, an antimicrobial compound used in soap, toothpaste, deodorant and many other products, can inhibit target genes in the malaria parasite during two crucial stages of its lifecycle in humans - the hepatic stage.READ MORE
Comments | 2 ADD COMMENT
lesley samm | Jan 18, 2018
BEST HEALTH My father was diagnosed by biopsy with Idiopathic Pulmonary Fibrosis in Jan. 2006. Our family Doctor prescribed actimmune and my father breathing tests and chest x-rays have not shown a change since the first ones.No dreaded side effects of the drug and feel blessed to be here. My father blood/oxygen was 95% and his main symptom was shortness of breath if he push too hard, when this occurs, he just rest. December 2017 i purchased IPF herbal formula from Best Health Herbal Centre, which my father used for only 5 weeks and he was IPF free 100%.His main symptom shortness of breath disappeared. Only the Almighty will bless Best Health Herbal Centre for their great work on human life.My father is now 76 years old and still very active. Purchase your IPF Formula via their Website ww w .besthealthherbalcentre. com
Ana Aitawa | Oct 03, 2017
The global idiopathic pulmonary fibrosis treatment market expected to reach US$ 3.5 billion by 2021, growing at CAGR 14.4% over the forecast period 2017-2021, owing to increasing drug prices and rapid approval of new treatments. Visit Idiopathic Pulmonary Fibrosis (IPF) Treatment Market by Treatment Type – Pharmacological Treatment (Pirfenidone (Esbriet), Nintedanib (Ofev), Generic Pirfenidone); Non-pharmacological Treatment (Oxygen Therapy, Pulmonary Rehabilitation, Mechanical Ventilation, Lung Transplantation, Other Non-Pharmacological Treatment); Patients by Disease Severity (Mild, Moderate, Severe); Drug Pipeline Analysis (AEOL-10150, Lebrikizumab, Tipelukast, Tralokinumab, FG-3019, Simtuzumab, BMS-986020, AF-219, SAR156597, BG00011, PRM-151, PBI-4050) at https://www.ihealthcareanalyst.com/report/idiopathic-pulmonary-fibrosis-treatment-market/